HomeCompareMCRPF vs MAIN

MCRPF vs MAIN: Dividend Comparison 2026

MCRPF yields 127.39% · MAIN yields 6.91%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MAIN wins by $42.84M in total portfolio value· pulled ahead in Year 4
10 years
MCRPF
MCRPF
● Live price
127.39%
Share price
$1.57
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$50.7K
Annual income
$32.01
Full MCRPF calculator →
MAIN
Main Street Capital Corporation
● Live price
6.91%
Share price
$52.96
Annual div
$3.66
5Y div CAGR
72.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$42.89M
Annual income
$35,818,348.00
Full MAIN calculator →

Portfolio growth — MCRPF vs MAIN

📍 MAIN pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMCRPFMAIN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MCRPF + MAIN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MCRPF pays
MAIN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MCRPF
Annual income on $10K today (after 15% tax)
$10,828.03/yr
After 10yr DRIP, annual income (after tax)
$27.21/yr
MAIN
Annual income on $10K today (after 15% tax)
$587.42/yr
After 10yr DRIP, annual income (after tax)
$30,445,595.80/yr
At 15% tax rate, MAIN beats the other by $30,445,568.59/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MCRPF + MAIN for your $10,000?

MCRPF: 50%MAIN: 50%
100% MAIN50/50100% MCRPF
Portfolio after 10yr
$21.47M
Annual income
$17,909,190.01/yr
Blended yield
83.42%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MAIN right now

MCRPF
No analyst data
Altman Z
0.5
Piotroski
4/9
MAIN
Analyst Ratings
2
Buy
11
Hold
Consensus: Hold
Price Target
$65.25
+23.2% upside vs current
Range: $60.00 — $70.00
Altman Z
1.7
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MCRPF buys
0
MAIN buys
0
No recent congressional trades found for MCRPF or MAIN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMCRPFMAIN
Forward yield127.39%6.91%
Annual dividend / share$2.00$3.66
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%72.7%
Portfolio after 10y$50.7K$42.89M
Annual income after 10y$32.01$35,818,348.00
Total dividends collected$18.5K$41.85M
Payment frequencyquarterlymonthly
SectorStockBDC

Year-by-year: MCRPF vs MAIN ($10,000, DRIP)

YearMCRPF PortfolioMCRPF Income/yrMAIN PortfolioMAIN Income/yrGap
1$17,069$6,369.43$12,434$1,193.51+$4.6KMCRPF
2$23,345$5,080.49$16,255$2,280.05+$7.1KMCRPF
3$28,226$3,246.85$22,851$4,580.08+$5.4KMCRPF
4← crossover$32,036$1,834.45$35,577$9,892.59$3.5KMAIN
5$35,251$972.93$63,653$23,664.70$28.4KMAIN
6$38,219$500.27$136,601$65,054.52$98.4KMAIN
7$41,148$253.46$368,044$214,504.02$326.9KMAIN
8$44,156$127.51$1,301,668$887,987.40$1.26MMAIN
9$47,311$63.94$6,288,483$4,825,407.47$6.24MMAIN
10$50,655$32.01$42,886,603$35,818,348.00$42.84MMAIN

MCRPF vs MAIN: Complete Analysis 2026

MCRPFStock

MicroPort Scientific Corporation, an investment holding company, manufactures, and markets, and distributes medical devices in the People's Republic of China, North America, Europe, other Asian countries, South America, and internationally. The company's Cardiovascular Devices segment offers products and services for the treatment of coronary artery-related diseases; coronary stents and related delivery systems; and balloon catheters and accessories. Its Orthopedics Devices segment provides reconstructive joints, spine and trauma, and other professional implants and instruments. The company's Cardiac Rhythm Management Business segment offers defibrillators, cardiac resynchronization therapy devices, and pacemakers for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. Its Endovascular and Peripheral Vascular Devices segment provides products and services for the interventional treatment of thoracic and abdominal aortic aneurysm, peripheral vascular diseases, aortic dissection, and other endovascular related diseases. The company's Neurovascular Devices segment offers neurovascular therapeutic and access devices for neurovascular diseases. Its Heart Valve Business segment provides VitaFlow Transcatheter aortic valve and delivery system, VitaFlow Liberty Transcatheter aortic valve implantation and retrievable delivery systems, Alwide Plus Balloon Catheter, various transcatheter aortic valve implantation, transcatheter mitral valve, transcatheter tricuspid valve, and surgical valve products. The company's Surgical Robot Business segment designs, develops, and commercializes surgical robots comprising robot ontology, control algorithm, electrical engineering, image-based navigation, and precision imaging. Its Surgical Devices segment researches and develops, manufactures, and sells surgical devices. MicroPort Scientific Corporation was founded in 1998 and is headquartered in Shanghai, the People's Republic of China.

Full MCRPF Calculator →

MAINBDC

Main Street Capital Corporation is a business development company specializes in equity capital to lower middle market companies. The firm specializing in recapitalizations, management buyouts, refinancing, family estate planning, management buyouts, refinancing, industry consolidation, mature, later stage emerging growth. The firm also provides debt capital to middle market companies for acquisitions, management buyouts, growth financings, recapitalizations and refinancing. The firm seeks to partner with entrepreneurs, business owners and management teams and generally provides one stop financing alternatives within its lower middle market portfolio. It prefers to invest in air freight and logistics, auto components, building products, chemicals, commercial services, computers, construction and engineering, consumer finance, consumer services, electronic equipment, energy equipment and services, financial services, health care equipment, health care providers, hotels, restaurants, and leisure, internet software and services, IT Services, machinery, oil, gas and consumable fuels, paper and forest products, professional and industrial services, road and rail, software, specialty retail, telecommunication, consumer discretionary, energy, materials, technology, and transportation. The firm typically invests in lower middle market companies generally with annual revenues between $5 million and $300 million. It prefers to invest in ranging between $2 million and $75 million in equity investment and enterprise value in ranging between $3 million and $20 million. The firm typically prefers to invest in the range of $5 million and $50 million per transaction in debt investment value and in the range of $1 million and $20 million in annual EBITDA. The firm's middle market debt investments are made in businesses that are generally larger in size than its lower middle market portfolio companies. It takes 5 percent minority and up to 50 percent majority equity investments. Main Street Capital Corporation was founded in 2007 and is based in Houston, Texas with an additional office in Chojnów, Poland.

Full MAIN Calculator →
📬

Get this MCRPF vs MAIN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MCRPF vs SCHDMCRPF vs JEPIMCRPF vs OMCRPF vs KOMCRPF vs ARCCMCRPF vs HTGCMCRPF vs GBDCMCRPF vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.